



Contents lists available at ScienceDirect

Chinese Chemical Letters

journal homepage: [www.elsevier.com/locate/cclet](http://www.elsevier.com/locate/cclet)

Original article

## Synthesis, antimicrobial, anti-quorum-sensing and cytotoxic activities of new series of benzothiazole derivatives

Q1 Moustafa T. Gabr<sup>a,b</sup>, Nadia S. El-Gohary<sup>a,\*</sup>, Eman R. El-Bendary<sup>a</sup>,  
Mohamed M. El-Kerdawy<sup>a</sup>, Nanting Ni<sup>b</sup>, Mona I. Shaaban<sup>c,d</sup><sup>a</sup> Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt<sup>b</sup> Department of Chemistry, Georgia State University, Atlanta, GA 30303, USA<sup>c</sup> Department of Microbiology, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt<sup>d</sup> Department of Microbiology, College of Pharmacy, Taibah University, Almadinah Almunawwarah 344, Saudi Arabia

## ARTICLE INFO

## Article history:

Received 31 March 2015

Received in revised form 6 July 2015

Accepted 18 August 2015

Available online xxx

## Keywords:

Benzothiazoles

Antimicrobial activity

Anti-quorum-sensing activity

Cytotoxic activity

*In silico* studies

## ABSTRACT

New series of benzothiazole derivatives were designed and synthesized. The newly synthesized compounds were screened for their antibacterial activity against *Escherichia coli*, *Staphylococcus aureus* and *Bacillus cereus*. Compounds **6j** and **6o** showed the highest activity against *E. coli* and *S. aureus*. The antifungal activity of these compounds was also tested against *Candida albicans* and *Aspergillus fumigatus* 293. Compounds **4c**, **4g** and **6j** exhibited the highest activity against *C. albicans*. In addition, compounds **4a** and **6j** displayed promising activity against *A. fumigatus* 293. The same compounds were examined for their anti-quorum-sensing activity against *Chromobacterium violaceum* ATCC 12472, whereas compounds **4a**, **6j** and **6p** showed moderate activity. The *in vitro* cytotoxicity testing of the synthesized compounds was performed against cervical cancer (Hela) and kidney fibroblast cancer (COS-7) cell lines. Results indicated that all tested compounds have IC<sub>50</sub> values >50 μM against both cell lines. Molecular properties, toxicities, drug-likeness, and drug score profiles of compounds **4a–c**, **5a**, **6g,h**, **6j**, **6l**, **6o** and **7c,d** were also assessed.

© 2015 Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences. Published by Elsevier B.V. All rights reserved.

## 1. Introduction

The traditional antibacterial agents either kill bacteria (bactericidal) or inhibit their growth (bacteriostatic). Typically, the targets for the conventional antibiotics are the essential cellular processes such as bacterial cell wall biosynthesis, bacterial protein synthesis, and bacterial DNA replication and repair [1]. The eventual growth arrest and cell death can be followed by rapid expansion of resistant subpopulations, making subsequent treatment difficult or impossible [2]. Therefore, new antibacterial strategies are required. An alternative to killing or inhibiting growth of pathogenic bacteria is the specific attenuation of bacterial virulence, which could be attained by targeting key regulatory systems that mediate the expression of virulence factors. One of the target regulatory systems is quorum sensing (QS) [1]. QS is a phenomenon used by bacteria for coordination of population-wide phenotypes, such as expression of

virulence genes, antibiotic resistance and biofilm formation. QS disruption is one of the emerging anti-virulence strategies that promises a lower risk of resistance development [3]. Many quorum quenching methods have been developed against various clinically significant bacterial pathogens [4].

The benzothiazole nucleus is a unique scaffold for further molecular exploration to synthesize novel compounds. Literature survey revealed that benzothiazole analogs are associated with diverse pharmacological effects, including antimicrobial activity [5–9]. In addition, benzothiazoles incorporating pyrazole moiety demonstrated remarkable antimicrobial activity [10,11]. On the same line, benzothiazoles incorporating isatin moiety have received considerable attention owing to their diverse chemotherapeutic potentials, including antimicrobial activity [12,13]. In addition, various Schiff bases of 2-hydrazinobenzothiazole derivatives (Fig. 1) were previously synthesized and screened for their antimicrobial activity [14–16]. Some of these derivatives displayed promising activity.

Therefore, we found it interesting to design new compounds within the scope of synthetic procedures using the benzothiazole

\* Corresponding author.

E-mail address: [dr.nadiaelgohary@yahoo.com](mailto:dr.nadiaelgohary@yahoo.com) (N.S. El-Gohary).





Fig. 1. Schiff bases of 2-hydrazinobenzothiazole derivatives with reported antimicrobial activity.

scaffold followed by suitable modifications to generate new series of compounds with expected antimicrobial activity. The manipulation strategy embraces the incorporation of pyrazole, isatin and arylidene moieties into the benzothiazole ring in order to verify the importance of these moieties for the antimicrobial activity (Fig. 2).

## 2. Experimental

A general approach for the synthesis of the designed compounds is outlined in Scheme 1. The starting compound, 2-amino-6-fluorobenzothiazole (**1**) was reacted with hydrazine hydrate in refluxing ethylene glycol in the presence of hydrochloric acid to produce the hydrazine derivative **2** [17]. Refluxing compound **2** with ethyl 3-oxo-2-((2-substituted phenyl)hydrazono)butanoates **3a-e** [18] in glacial acetic acid yielded the corresponding pyrazole analogs **4a-e**. In addition, the reaction of the key intermediate **2** with the appropriate isatin in ethanol in the presence of glacial acetic acid gave compounds **5a-c**. Reaction of **2** with the appropriate aromatic aldehyde in ethanol under microwave irradiation gave the corresponding Schiff bases **6a-r** in 64–82% yields. Moreover, refluxing the hydrazine analog **2** with the appropriate acetophenone in ethanol in the presence of glacial acetic acid furnished compounds **7a-d** in 61–73% yields. The synthesized compounds, **4a-e**, **5a-c**, **6a-r** and **7a-d** were screened for their *in vitro* antibacterial activity against two species of Gram-positive bacteria (*Staphylococcus aureus* and *Bacillus cereus*) and one Gram-negative bacterium (*Escherichia coli*) [19,20]. Antifungal screening against *Candida albicans* and *Aspergillus fumigatus* 293 was also performed [20,21]. The same compounds were examined for their anti-quorum-sensing activity against *Chromobacterium violaceum* ATCC 12472 [22]. Additionally, the *in vitro*

cytotoxicity testing of compounds **4a-e**, **5a-c**, **6a-r** and **7a-d** was performed against cervical cancer (Hela) and kidney fibroblast cancer (COS-7) cell lines adopting MTT assay [23–25].

The synthetic details and related spectra of the compounds as well as their biological testing are deposited in Supporting information.

## 3. Results and discussion

### 3.1. Chemistry

The structures of all the synthesized compounds were confirmed by <sup>1</sup>H NMR, <sup>13</sup>C NMR and HRMS. <sup>1</sup>H NMR spectra of compounds **4a-e** showed a characteristic singlet signal at δ 2.05–2.50 ppm for the methyl protons at the 3-position of the pyrazole ring. In the <sup>1</sup>H NMR spectra of compounds **6a-r**, a singlet signal at δ 7.95–8.83 ppm was due to CH=N proton. Regarding <sup>1</sup>H NMR spectra of compounds **7a-d**, methyl protons were observed as a singlet signal at δ 1.90–2.35 ppm.

### 3.2. Biological screening

The antimicrobial screening results (Table 1) were determined by measuring the average diameter of the inhibition zones, expressed in millimeters (mm) [19,21]. The minimum inhibitory concentration (MIC, μg/mL) of the most active compounds against *E. coli*, *S. aureus*, *C. albicans* and *A. fumigatus* 293 was carried out by broth microdilution method using 96-multiwell microtiter plates [20]. As shown in the results (Table 2), compound **6j** showed the highest activity against *E. coli* with MIC value of 312 μg/mL. Furthermore, compound **6j** exhibited good antibacterial activity against *S. aureus* with MIC value of 156.25 μg/mL. The results are compared to ampicillin as a reference antibacterial agent. Regarding the antifungal activity, compounds **4c**, **6g** and **6j** displayed the highest activity against *C. albicans* with MIC value of 312.5 μg/mL. In addition, compounds **4a** and **6j** demonstrated strong antifungal activity against *A. fumigatus* 293 with MIC value of 156.25 μg/mL (Table 2). The results are compared to fluconazole as a reference antifungal agent. *A. fumigatus* 293 was resistant to fluconazole [26]. These observations may promote further development of benzothiazole derivatives and may lead to compounds with potent antibacterial and antifungal activities.

While antibiotics kill or slow down the growth of bacteria, quorum sensing inhibitors (QSIs) or quorum quenchers (QQs) attenuate bacterial virulence and appear to be a promising strategy to control bacterial resistance to antibiotics [27]. Thus, the same compounds were examined for anti-quorum-sensing activity





Fig. 2. Designed strategy of the titled compounds.



Comp. No.	Ar	Comp. No.	Ar	Comp. No.	Ar
<b>6a</b>		<b>6b</b>		<b>6c</b>	
<b>6d</b>		<b>6e</b>		<b>6f</b>	
<b>6g</b>		<b>6h</b>		<b>6i</b>	
<b>6j</b>		<b>6k</b>		<b>6l</b>	
<b>6m</b>		<b>6n</b>		<b>6o</b>	
<b>6p</b>		<b>6q</b>		<b>6r</b>	

Scheme 1. Synthesis of compounds **4a-e**, **5a-c**, **6a-r** and **7a-d**.

against *Ch. violaceum* ATCC 12472 [22]. The QS system of *Ch. violaceum* was used for this assay. QS in this wild type strain of bacteria produces violacein (a purple pigment) in response to autoinducer molecules known as acyl HSLs [28,29]. Thus, drugs

that inhibit acyl HSL-mediated QS activity in *Ch. violaceum* would prevent the production of this purple pigment. Screening results for their ability to inhibit QS regulated violacein production against *Ch. violaceum* (based on measuring the radius of pigment inhibition

122  
123  
124  
125

**Table 1**  
Antimicrobial and anti-quorum-sensing activities of compounds **4a–e**, **5a–c**, **6a–r** and **7a–d**.

Comp. No.	Inhibition zone diameter (mm) <sup>a,b</sup>					QS inhibition (mm) <sup>c</sup>
	<i>E. coli</i>	<i>B. cereus</i>	<i>S. aureus</i>	<i>C. albicans</i>	<i>A. fumigatus</i>	<i>Ch. violaceum</i>
<b>4a</b>	6	8	–	–	<b>28</b>	11
<b>4b</b>	3	6	4	<b>17</b>	–	6
<b>4c</b>	4	8	4	<b>28</b>	–	–
<b>4d</b>	4	4	–	–	5	4
<b>4e</b>	4	4	–	–	5	4
<b>5a</b>	–	–	–	2	<b>26</b>	–
<b>5b</b>	2	2	2	2	14	4
<b>5c</b>	–	–	–	–	–	4
<b>6a</b>	2	3	–	–	–	–
<b>6b</b>	5	7	–	–	–	–
<b>6c</b>	–	–	–	–	–	–
<b>6d</b>	5	3	14	–	–	–
<b>6e</b>	–	14	–	7	–	–
<b>6f</b>	–	2	3	10	–	6
<b>6g</b>	14	10	11	<b>19</b>	–	–
<b>6h</b>	–	8	–	8	<b>17</b>	–
<b>6i</b>	5	4	3	10	–	–
<b>6j</b>	<b>18</b>	14	<b>26</b>	<b>28</b>	<b>32</b>	14
<b>6k</b>	–	–	3	4	–	–
<b>6l</b>	2	4	4	6	<b>20</b>	–
<b>6m</b>	4	8	10	6	–	–
<b>6n</b>	–	4	–	8	–	5
<b>6o</b>	<b>16</b>	12	<b>19</b>	12	–	–
<b>6p</b>	–	5	5	7	–	14
<b>6q</b>	–	3	–	–	–	–
<b>6r</b>	5	4	15	–	–	–
<b>7a</b>	–	–	–	–	11	–
<b>7b</b>	4	2	–	–	–	–
<b>7c</b>	–	–	–	–	<b>26</b>	–
<b>7d</b>	–	2	–	2	<b>30</b>	–
Ampicillin	26	12	30	nt	nt	nt
Fluconazole	nt	nt	nt	22	–	nt
Catechin	nt	nt	nt	nt	nt	4

Bold values point out the best results. nt, not tested.

<sup>a</sup> Results are calculated after subtraction of DMSO activity.

<sup>b</sup> Not active (–, inhibition zone <2 mm); weak activity (2–9 mm); moderate activity (10–15 mm); strong activity (16–25 mm); very strong activity (26–35 mm).

<sup>c</sup> QS inhibition (radius of pigment inhibition in mm) = radius of growth and pigment inhibition ( $r_2$ ) – radius of bacterial growth inhibition ( $r_1$ ).

**Table 2**  
MIC values of the most active compounds.

Comp. No.	MIC ( $\mu\text{g/mL}$ ) <sup>a</sup>			
	<i>E. coli</i>	<i>S. aureus</i>	<i>C. albicans</i>	<i>A. fumigatus</i>
<b>4a</b>	nt	nt	nt	156.25
<b>4b</b>	nt	nt	625	nt
<b>4c</b>	nt	nt	312.5	nt
<b>5a</b>	nt	nt	nt	312.5
<b>6g</b>	nt	nt	312.5	nt
<b>6h</b>	nt	nt	nt	625
<b>6j</b>	312.5	156.25	312.5	156.25
<b>6l</b>	nt	nt	nt	625
<b>6o</b>	625	625	nt	nt
<b>7c</b>	nt	nt	nt	312.5
<b>7d</b>	nt	nt	nt	312.5
Ampicillin	19.531	312.5	nt	nt
Fluconazole	nt	nt	1250	–

<sup>a</sup> –, MIC > 2500  $\mu\text{g/mL}$ . nt, not tested.

### 3.3. Structure–activity relationship (SAR) studies

Compounds **4a–e**: Removal of the 2-chloro substituent from the phenyl ring of compound **4a** increased the activity against *C. albicans* but abolished the activity against *A. fumigatus* 293 (compound **4b**). Moreover, replacement of the 4-nitro substituent in the same compound with 4-chloro substituent resulted in excellent activity against *C. albicans* (compound **4c**) but abolished activity against *A. fumigatus* 293. Compounds bearing 2,4-disubstituted phenyl and 4-substituted phenyl moieties exhibited stronger activity against *C. albicans* compared to compounds bearing 2,5-disubstituted phenyl moiety (compounds **4b,c** vs. **4d,e**).

Compounds **5a–c**: Replacement of 2-oxoindolin-3-ylidene moiety (compound **5a**) with 5-bromo-2-oxoindolin-3-ylidene (compound **5b**) resulted in decreased antifungal activity against *A. fumigatus* 293, while its replacement with 5-methyl-2-oxoindolin-3-ylidene abolished the antifungal activity against both of the tested fungi (compound **5c**).

Compounds **6a–r**: Compounds **6a,b** bearing (furan-2-yl)methylene moiety were inactive as antifungal agents and revealed weak activity against *E. coli* and *B. cereus*. Replacement of (furan-2-yl)methylene moiety with (1*H*-pyrrol-2-yl)methylene moiety completely abolished the antibacterial activity against *E. coli* and *B. cereus* (compound **6c** vs. **6a,b**). The presence of 2-nitrobenzylidene moiety resulted in acceptable antibacterial activity against the three tested microorganisms as well as antifungal activity against *C. albicans* (compound **6g**), while its replacement with 2-bromobenzylidene or 2-cyanobenzylidene

in mm) are presented in Table 1 and revealed that compounds **4a**, **6j** and **6p** have moderate anti-quorum-sensing activity. The rest of the tested compounds were found to be less active or completely inactive. The results are compared to catechin as a positive control. The results of *in vitro* cytotoxicity testing against cervical cancer (Hela) and kidney fibroblast cancer (COS-7) cell lines indicated that all tested compounds have IC<sub>50</sub> values >50  $\mu\text{M}$  against both cell lines.

161 resulted in decreased antibacterial and antifungal activities  
162 (compounds **6i** and **6k**). Furthermore, the presence of 3-hydroxybenzylidene moiety revealed strong antifungal activity against  
163 *A. fumigatus* 293 (compound **6h**). Incorporation of 3,4-dihydroxybenzylidene moiety into the benzothiazole nucleus resulted in  
164 promising activity against *E. coli*, *S. aureus*, *C. albicans* and *A. fumigatus* 293 as well as moderate anti-quorum-sensing activity  
165 (compound **6j**). Replacement of 4-*N,N*-dimethylaminobenzylidene moiety with 4-*N,N*-diethylamino-2-hydroxybenzylidene  
166 increased the antibacterial activity against the three tested microorganisms but abolished the antifungal activity against *A.*  
167 *fumigatus* 293 (compound **6m** vs. **6l**). Replacement of (pyridin-2-yl)methylene moiety with (3,5-dichloropyridin-4-yl)methylene  
168 increased the antibacterial activity against the three tested microorganisms as well as antifungal activity against *C. albicans*  
169 (compound **6o** vs. **6n**). Incorporation of (isoquinolin-5-yl)methylene moiety into the benzothiazole nucleus improved the  
170 anti-quorum-sensing activity (compound **6p**), while incorporation of (pyren-2-yl)methylene moiety enhanced the antibacterial  
171 activity against *S. aureus* (compound **6r**).

181 Compounds **7a-d**: The presence of 2-hydroxy-5-methylphenyl and 4-iodophenyl moieties resulted in promising antifungal activity  
182 against *A. fumigatus* 293 (compounds **7c,d**), while incorporation of 5-bromo-2-hydroxyphenyl moiety into the benzothiazole nucleus  
183 resulted in moderate antifungal activity against the same microorganism (compound **7a**). On the other hand, incorporation  
184 of 3-hydroxy-2-methoxyphenyl moiety abolished the antifungal activity against the same microorganism (compound **7b**).

### 189 3.4. Molecular properties and drug-likeness

190 A molecular property is a complex balance of various structural features which determine whether a particular molecule is similar  
191 to the known drugs. It generally means "molecules which contain functional groups and/or have physical properties consistent with  
192 most of the known drugs". Hydrophobicity, molecular size, flexibility and presence of various pharmacophoric features are  
193 the main physical properties that influence the behavior of molecules in a living organism. Computational chemists have a  
194 wide array of tools and approaches available for the assessment of molecular diversity. Diversity analysis has been shown to be an  
195 important ingredient in designing drugs. So, computational sensitivity and structural analyses have been used to study the  
196 drug-likeness of the candidate drug. As good bioavailability can be achieved with an appropriate balance between solubility and  
197 partitioning properties. Thus, in order to achieve good oral drugs,

**Table 3**

Topological polar surface area, number of rotatable bonds and calculated Lipinski's rule of five for compounds **4a-c**, **5a**, **6g,h**, **6j**, **6l**, **6o** and **7c,d**.

Comp. No.	Molecular properties						
	TPSA <sup>a</sup>	Nrotb <sup>b</sup>	miLogP <sup>c</sup>	OH-NH interact	O-N interact	MW	No. of violations
<b>4a</b>	118.04	4	4.406	1	9	432.8	0
<b>4b</b>	118.00	4	3.800	1	9	398.39	0
<b>4c</b>	72.18	3	5.125	1	6	422.7	1
<b>5a</b>	70.145	2	3.695	2	5	312.2	0
<b>6g</b>	83.107	4	3.838	1	6	316.3	0
<b>6h</b>	57.511	3	3.424	2	4	287.3	0
<b>6j</b>	77.739	3	2.958	3	5	303.3	0
<b>6l</b>	40.521	4	4.029	1	4	314.4	0
<b>6o</b>	50.175	3	4.286	1	4	341.1	0
<b>7c</b>	57.511	3	4.738	2	4	315.3	0
<b>7d</b>	37.283	3	5.456	1	3	411.2	1
Ampicillin	112.73	4	-0.87	4	7	349.4	0
Fluconazole	81.664	5	-0.118	1	7	306.2	0

<sup>a</sup> TPSA, topological polar surface area.

<sup>b</sup> Nrotb, number of rotatable bonds.

<sup>c</sup> miLogP, the parameter of lipophilicity.

205 compounds **4a-c**, **5a**, **6g,h**, **6j**, **6l**, **6o** and **7c,d** which exhibited the  
206 highest antibacterial and/or antifungal activity, were analyzed for  
207 the prediction of solubility and Lipinski's rule of five [30] as well as  
208 other properties (Tables 3 and 4) for filtering compounds for  
209 subsequent synthesis and antimicrobial screening.

### 210 3.4.1. Molinspiration calculations

211 As a part of our study; the compliance of compounds to the  
212 Lipinski's rule of five was evaluated [30], this simple rule is based  
213 on the observation that most biologically active drugs have  
214 molecular weight of 500 or less, logP values not higher than 5,  
215 hydrogen bond donor sites not higher than 5 and hydrogen bond  
216 acceptor sites not higher than 10. In addition, topological polar  
217 surface area (TPSA) and number of rotatable bonds have been  
218 linked to drug bioavailability [31]. Molecular properties (TPSA,  
219 nrotb, miLogP, OH-NH interaction, O-N interaction, molecular  
220 weight and number of violations from Lipinski's rule) of the newly  
221 synthesized compounds were calculated using molinspiration  
222 software and compared to the values of the standard drugs,  
223 ampicillin and fluconazole (Table 3).

224 Topological polar surface area (TPSA) and number of rotatable  
225 bonds are two important properties for the prediction of oral  
226 bioavailability of drug molecules [32-35]. TPSA is calculated based

**Table 4**

Toxicity risks, drug-likeness and drug score of compounds **4a-c**, **5a**, **6g,h**, **6j**, **6l**, **6o** and **7c,d**.

Comp. No.	Toxicity risks				Drug-likeness	Drug score
	Mutagenicity	Tumorigenicity	Irritancy	Reproductive effects		
<b>4a</b>	■	■	■	■	1.13	0.08
<b>4b</b>	■	■	■	■	-6.99	0.18
<b>4c</b>	■	■	■	■	4.83	0.20
<b>5a</b>	■	■	■	■	3.92	<b>0.62</b>
<b>6g</b>	■	■	■	■	0.94	0.15
<b>6h</b>	■	■	■	■	1.49	<b>0.52</b>
<b>6j</b>	■	■	■	■	2.35	<b>0.60</b>
<b>6l</b>	■	■	■	■	0.45	0.25
<b>6o</b>	■	■	■	■	1.45	0.40
<b>7c</b>	■	■	■	■	-0.27	0.35
<b>7d</b>	■	■	■	■	0.93	0.31
Ampicillin	■	■	■	■	10.72	0.91
Fluconazole	■	■	■	■	1.99	0.87

Bold values point out the best drug score values.

■ low risk; ■ high risk.

on the methodology published by Ertl et al. [35] as the surface areas that are occupied by oxygen and nitrogen atoms and by hydrogen atoms attached to them. Thus, it is closely related to the hydrogen bonding potential of a compound [32–35]. TPSA has been shown to be a very good descriptor characterizing drug absorption, including intestinal absorption, bioavailability and blood–brain barrier penetration. Molecules with TPSA values around 140 Å<sup>2</sup> or more are expected to exhibit poor intestinal absorption [31]. Results shown in Table 3 indicated that all of the analyzed compounds have TPSA values <140 Å<sup>2</sup>; thus, they are expected to have good intestinal absorption. Molecules with more than 10 rotatable bonds may have problems with bioavailability [31]. All the tested compounds have 2 to 4 rotatable bonds and they might not have problems with bioavailability (Table 3). MiLogP is calculated adopting the methodology developed by Molinspiration as a sum of fragment-based contributions and correction factors (<http://www.molinspiration.com>). It has been shown that for the compound to have a reasonable probability of being well absorbed, miLogP value must be in the range of –0.4 to +5 [31]. On this basis, all compounds under investigation (except **4c** and **7d**) were found to have miLogP values under the acceptable criteria and they are expected to have reasonable oral absorption (Table 3). It is worth mentioning that all of the analyzed compounds have one or zero violation of Lipinski's rule; therefore, they are expected not to have problems with bioavailability (Table 3). Molecules violating more than one may have problems with bioavailability [36].

#### 3.4.2. Osiris calculations

Toxicity risks (mutagenicity, tumorigenicity, irritancy and reproductive effects) and physicochemical properties (drug-likeness and drug score) of the synthesized compounds were calculated by the methodology developed by Osiris [32]. The toxicity risk predictor locates fragments within a molecule which indicate a potential toxicity risk. Toxicity risk alerts indicate that the drawn structure may be harmful concerning the risk category specified. From the data presented in Table 4, it is obvious that the analyzed compounds are supposed to be non-mutagenic (except **4a** and **6g**), non-tumorigenic (except **4a**, **6g** and **6l**), non-irritating, and with no reproductive effects (except **4a–c**).

Drug-likeness is defined as a complex balance of various molecular properties and structural features which indicates whether a particular molecule is similar to the known drugs or not [37]. Osiris program was used for calculating the fragment-based drug-likeness of compounds **4a–c**, **5a**, **6g,h**, **6j**, **6l**, **6o** and **7c,d**, a positive value indicates that the designed molecule contains fragments which are frequently present in commercial drugs. Results shown in Table 4 indicated that compounds **4c**, **5a** and **6j** have higher drug-likeness values than the standard drug, fluconazole. The drug score combines drug-likeness, miLogP, solubility, molecular weight and toxicity risks in one handy value that may be used to judge the compound's overall potential to qualify for a drug [32]. A value of 0.5 or more makes the compound a promising lead for future development of safe and efficient drugs. The overall drug score values for compounds **4a–c**, **5a**, **6g,h**, **6j**, **6l**, **6o** and **7c,d** were calculated and compared to that of the standard drugs, ampicillin and fluconazole. Compounds **5a**, **6h** and **6j** possess good drug score values (Table 4).

## 4. Conclusion

In a summary, compounds **6j** and **6o** are good antibacterial agents. Compounds **4c** and **6j** showed the highest antifungal activity against *C. albicans*. In addition, compounds **4a** and **6j** displayed the best antifungal activity against *A. fumigatus* 293. Furthermore, compounds **4a**, **6j** and **6p** showed moderate

antiquorum-sensing activity. These active compounds were proved to be good scaffolds for the development of new potent antibacterial and antifungal agents.

## Conflict of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

## Acknowledgments

The authors thank Professor Binghe Wang at Georgia State University, USA, for providing all required facilities and carrying out the spectral analyses as well as the cytotoxicity testing.

## Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.ccllet.2015.09.004>.

## References

- [1] T. Defoirdt, N. Boon, P. Bossier, Can bacteria evolve resistance to quorum sensing disruption? *PLoS Pathog.* 6 (7) (2010) e1000989. <http://dx.doi.org/10.1371/journal.ppat.1000989>.
- [2] G. Werner, B. Strommenger, W. Witte, Acquired vancomycin resistance in clinically relevant pathogens, *Future Microbiol.* 3 (2008) 547–562.
- [3] L. Cegelski, G.R. Marshall, G.R. Eldridge, S.J. Hultgren, The biology and future prospects of antivirulence therapies, *Nat. Rev. Microbiol.* 6 (2008) 17–27.
- [4] S.B. Tay, W.S. Yew, Development of quorum-based anti-virulence therapeutics targeting Gram-negative bacterial pathogens, *Int. J. Mol. Sci.* 14 (2013) 16570–16599.
- [5] S. Agarwal, D.K. Agarwal, N. Gautam, K. Agarwal, D.C. Gautam, Synthesis and *in vitro* antimicrobial evaluation of benzothiazole incorporated thiazolidin-4-ones derivatives, *J. Korean Chem. Soc.* 58 (2014) 33–38.
- [6] M.K. Singha, R. Tilak, G. Nath, S.K. Awasthi, A. Agarwal, Design, synthesis and antimicrobial activity of novel benzothiazole analogs, *Eur. J. Med. Chem.* 63 (2013) 635–644.
- [7] S. Yilmaz, I. Yalcin, F. Kaynak-Onurdag, S. Ozgen, I. Yildiz, E. Aki, Synthesis and *in vitro* antimicrobial activity of novel 2-(4-(substituted-carboxamido)benzyl)phenyl)benzothiazoles, *Croat. Chem. Acta* 86 (2013) 223–231.
- [8] P. Patel, J. Pillai, N. Darji, P. Patel, B. Patel, Design, synthesis and characterization of novel molecules comprising benzothiazole and sulphonamide linked to substituted aryl group via azo link as potent antimicrobial agents, *Int. J. Drug Res. Technol.* 2 (2012) 289–296.
- [9] K.A. Goud, J.N. Narendra, L.V.G. Nargund, L.N. Shachindra, V. Chidvila, S. Ramya silpa, V. Balakrishna, Synthesis of novel benzothiazoles for anti-bacterial activity, *Der Pharm. Chem.* 4 (2012) 1408–1414.
- [10] E.S. Darwish, A.M. Abdel Fattah, F.A. Attaby, O.N. Al-Shayea, Synthesis and antimicrobial evaluation of some novel thiazole, pyridone, pyrazole, chromene, hydrazone derivatives bearing a biologically active sulfonamide moiety, *Int. J. Mol. Sci.* 15 (2014) 1237–1254.
- [11] O.M.O. Habib, H.M. Hassan, E.B. Moawad, A. El-Mekabaty, Reactivity of oxazolone derivative towards nitrogen and carbon nucleophilic reagents: applications to the synthesis of new heterocycles, *Int. J. Modern Org. Chem.* 2 (2013) 11–25.
- [12] K.O. Badahdah, H.M. Abdel Hamid, S.A. Noureddin, Functionalized 2-hydrazino-benzothiazole with isatin and some carbohydrates under conventional and ultrasound methods and their biological activities, *J. Heterocyclic Chem.* 52 (2015) 67–74.
- [13] A. Aboelmagd, I.A.I. Ali, E.M.S. Salem, M. Abdel-Razik, Synthesis and antifungal activity of some 2-benzothiazolylthioacetyl amino acid and peptide derivatives, *ARKIVOC* ix (2011) 337–353.
- [14] G. Alang, R. Kaur, G. Kaur, A. Singh, P. Singla, Synthesis and antibacterial activity of some new benzothiazole derivatives, *Acta Pharm. Sci.* 52 (2010) 213–218.
- [15] G. Alang, R. Kaur, A. Singh, P. Budhlakoti, A. Singh, R. Sanwal, Synthesis, characterization and antifungal activity of certain (E)-1-(1-(substitutedphenyl)ethylidene)-2-(6-methylbenzo[d]thiazol-2-yl)hydrazine analogues, *Int. J. Pharm. Biol. Arch.* 1 (2010) 56–61.
- [16] H.K. Barot, G. Mallika, B.B. Sutariya, J. Shukla, L.V.G. Nargund, Synthesis of nitrogen mustards of fluoro-benzothiazoles of pharmacological interest, *Res. J. Pharm. Biol. Chem. Sci.* 1 (1) (2010) 124–129.
- [17] P. Yadav, D. Chauhan, N.K. Sharma, S. Singhal, 2-Substituted hydrazino-6-fluoro-1,3-benzothiazole: Synthesis and characterization of new novel antimicrobial agents, *Int. J. ChemTech Res.* 2 (2010) 1209–1213.
- [18] A.K. Pareek, P.E. Joseph, D.S. Seth, Novel and efficient synthesis and spectral evaluation of certain new substituted pyrazolones, *Orient. J. Chem.* 25 (2009) 203–206.

- [19] R.D. Pearson, R.T. Steigbigel, H.T. Davis, S.W. Chapman, Method for reliable determination of minimal lethal antibiotic concentrations, *Antimicrob. Agents Chemother.* 18 (1980) 699-708.
- [20] J.M. Andrews, Determination of minimum inhibitory concentrations, *J. Antimicrob. Chemother.* 48 (2001) 5-16.
- [21] R.J. Holt, Laboratory tests of antifungal drugs, *J. Clin. Pathol.* 28 (1975) 767-774.
- [22] K.H. McClean, M.K. Winson, L. Fish, A. Taylor, S.R. Chhabra, M. Camara, M. Daykin, J.H. Lamb, S. Swift, B.W. Bycroft, G.S. Stewart, P. Williams, Quorum sensing and *Chromobacterium violaceum*: exploitation of violacein production and inhibition for the detection of *N*-acyl homoserine lactones, *Microbiology* 143 (1997) 3703-3711.
- [23] T. Mosmann, Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays, *J. Immunol. Methods* 65 (1983) 55-63.
- [24] F. Denizot, R. Lang, Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability, *J. Immunol. Methods* 89 (1986) 271-277.
- [25] D. Gerlier, T. Thomasset, Use of MTT colorimetric assay to measure cell activation, *J. Immunol. Methods* 94 (1986) 57-63.
- [26] Clinical Laboratory Standard Institute (CLSI), Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi, Approved standard. M38-A2, Clinical Laboratory Standard Institute, Wayne, PA, USA, 2008.
- [27] A.K. Bhardwaj, K. Vinothkumar, N. Rajpara, Bacterial quorum sensing inhibitors: attractive alternatives for control of infectious pathogens showing multiple drug resistance, *Recent Pat. Antiinfect. Drug Discov.* 8 (2013) 68-83.
- [28] G.A. Mohamed, S.R. Ibrahim, M.I. Shaaban, S.A. Ross, Mangostanaxanthones I and II, new xanthones from the pericarp of *Garcinia mangostana*, *Fitoterapia* 98 (2014) 215-221.
- [29] O.M. Vandeputte, M. Kiendrebeogo, S. Rajaonson, B. Diallo, A. Mol, M. El Jaziri, M. Baucher, Identification of catechin as one of the flavonoids from *Combretum albiflorum* bark extract that reduces the production of quorum-sensing-controlled virulence factors in *Pseudomonas aeruginosa* PAO1, *Appl. Environ. Microbiol.* 76 (2010) 243-253.
- [30] C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, *Adv. Drug Deliv. Rev.* 46 (2001) 3-26.
- [31] D.F. Veber, S.R. Johnson, H.Y. Cheng, B.R. Smith, K.W. Ward, K.D. Kopple, Molecular properties that influence the oral bioavailability of drug candidates, *J. Med. Chem.* 45 (2002) 2615-2623.
- [32] A. Jarrahpour, J. Fathi, M. Mimouni, T. Ben Hadda, J. Sheikh, Z.H. Chohan, A. Parvez, Petra, Osiris and Molinspiration (POM) together as a successful support in drug design: antibacterial activity and biopharmaceutical characterization of some azo Schiff bases, *Med. Chem. Res.* 19 (2011) 1-7.
- [33] A. Parvez, M. Jyotsna, M.H. Youssoufi, T. Ben Hadda, Theoretical calculations and experimental verification of the antibacterial potential of some monocyclic beta-lactams containing two synergetic buried antibacterial pharmacophore sites, *Phosphorus Sulfur Silicon Relat. Elem.* 7 (2010) 1500-1510.
- [34] A. Parvez, J. Meshram, V. Tiwari, J. Sheikh, R. Dongre, M.H. Youssoufi, T. Ben Hadda, Pharmacophores modeling in terms of prediction of theoretical physicochemical properties and verification by experimental correlations of novel coumarin derivatives produced via Betti's protocol, *Eur. J. Med. Chem.* 45 (2010) 4370-4378.
- [35] P. Ertl, B. Rohde, P. Selzer, Fast calculation of molecular polar surface area (PSA) as a sum of fragment-based contributions and its application to the prediction of drug transport properties, *J. Med. Chem.* 43 (2000) 3714-3717.
- [36] C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, *Adv. Drug Deliv. Rev.* 23 (1997) 4-25.
- [37] O. Ursu, A. Rayan, A. Goldblum, T. Oprea, Understanding drug-likeness, *WIREs Comput. Mol. Sci.* 1 (2011) 760-781.